Eli Lilly is at the head of the pharma pack today, but in a decade, the situation could look very different.

LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.

Eli Lilly has been a growth beast in recent years, but its valuation has gotten fairly high along the way.

Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been ...

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.

The drugmaker unveiled a new Zepbound delivery system as its main rival absorbed fresh clinical and stock-market blows. It’s ...

Eli Lilly is making headlines in the pharmaceutical sector, but it's a very expensive stock.

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

Sept 9 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab on Monday said it has appointed insider Lucas Montarce as its new chief financial officer, effective immediately, months after former ...

Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to the career path of his predecessor, Anat Ashkenazi, who also spent two ...